venBio

News

Home News

News

2021
28JAN
Artiva Biotherapeutics Announces Exclusive Worldwide Collaboration and License Agreement with Merck to Develop Candidate CAR-NK Cell Therapies
posted by admin in Latest News

Read More
2021
08JAN
Positive Phase 2b ICONA Interim Results for icosabutate in NASH Patients
posted by admin in Latest News

Read More
2021
05JAN
Artiva Biotherapeutics Announces Appointment of Dr. Fred Aslan as President and CEO
posted by admin in Latest News

Read More
2020
08DEC
Barely two months after unveiling a new breed of radiopharmaceuticals, RayzeBio brings total haul to $150M
posted by admin in Latest News

Read More
2020
01DEC
Tallac Therapeutics Launches with $62 Million in Series A Financing to Advance Novel Immunotherapies for Cancer
posted by admin in Latest News

Read More
2020
18NOV
Elevation Oncology Announces $65M Series B Financing and Promotion of Founder Shawn M. Leland to Chief Executive Officer
posted by admin in Latest News

Read More
2020
18NOV
Pharvaris Announces $80 Million Series C Financing to Advance Novel Oral Bradykinin-B2-Receptor Antagonists for the Treatment of HAE
posted by admin in Latest News

Read More
2020
13NOV
Pharvaris Presents Clinical Data at ACAAI 2020 Demonstrating Safety and Therapeutic Potential of Oral PHA121 for the Treatment of HAE
posted by admin in Latest News

Read More
2020
09NOV
Stargazer Pharmaceuticals, Inc. Announces $57 Million Series A Financing and Initiation of a Phase 2a Clinical Study of STG-001 in Stargardt Disease Patients
posted by admin in Latest News

Read More
2020
09NOV
ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Promising Initial Clinical Responses in Patients with Advanced Solid Tumors
posted by admin in Latest News

Read More
2020
14OCT
RayzeBio Launches with $45 Million Series A to Advance Portfolio of Targeted Radiopharmaceuticals for Cancer Therapeutics
posted by admin in Latest News

Read More
2020
14OCT
Harmony Biosciences Receives FDA Approval For Expanded Use Of WAKIX® (pitolisant) For The Treatment Of Cataplexy In Adult Patients With Narcolepsy
posted by admin in Latest News

Read More
2020
15SEP
Metacrine Announces Pricing of Initial Public Offering
posted by admin in Latest News

Read More
2020
14SEP
Attralus Launches with $25 Million Series A Financing from venBio Partners to Transform Treatment for Patients with Systemic Amyloidosis
posted by admin in Latest News

Read More
2020
18AUG
Harmony Biosciences Announces Pricing Of Upsized Initial Public Offering
posted by admin in Latest News

Read More
2020
06AUG
Checkmate Pharmaceuticals Announces Pricing of Initial Public Offering
posted by admin in Latest News

Read More
2020
16JUL
ALX Oncology Announces Pricing of Initial Public Offering
posted by admin in Latest News

Read More
2020
30JUN
Akero Announces Strongly Positive Histological Data Across All Efruxifermin Dose Groups in 16-Week Phase 2a BALANCED Study in NASH Patients
posted by admin in Latest News

Read More
2020
26JUN
Artiva Biotherapeutics Launches with $78 Million Series A Financing to Advance NK Cell Therapies to Treat Cancer
posted by admin in Latest News

Read More
2020
10JUN
Checkmate Pharmaceuticals Secures $85 Million in Series C Financing
posted by admin in Latest News

Read More
2020
09JUN
NFlection Therapeutics Launches with $20M Series A Funding to Advance Lead Program in Neurofibromatosis
posted by admin in Latest News

Read More
2020
08APR
Roche makes a platform play, betting $190M in cash on Arrakis’ long-haul plans to drug RNA
posted by admin in Latest News

Read More
2020
03APR
venBio Closes $394 Million Life Sciences Venture Capital Fund
posted by admin in Latest News

Read More
2020
31MAR
All AKR-001 Dose Groups Met Week 12 Efficacy Endpoints in NASH Phase 2a BALANCED Study
posted by admin in Latest News

Read More
2020
12FEB
ALX Oncology Announces Closing of $105 Million Series C Financing
posted by admin in Latest News

Read More
2020
08JAN
NorthSea Therapeutics Announces US $40 Million Series B Financing to Complete Phase IIb ICONA study in NASH and to Advance Two Additional SEFAs into the Clinic
posted by admin in Latest News

Read More
2020
07JAN
Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
posted by admin in Latest News

Read More
2019
05NOV
Checkmate Pharmaceuticals Presents Positive Clinical Data with CMP-001
posted by admin in Latest News

Read More
2019
03OCT
Aeovian Pharmaceuticals Raises $37 Million Series A Financing to Advance Selective mTORC1 Inhibitors
posted by admin in Latest News

Read More
2019
10SEP
Pharvaris Announces $66 Million Series B Financing to Advance the Clinical Development of an Oral Therapy for Hereditary Angioedema
posted by admin in Latest News

Read More
2019
15AUG
Harmony Biosciences Announces FDA Approval Of WAKIX® (Pitolisant)
posted by admin in Latest News

Read More
2019
19JUN
Akero Therapeutics Announces Pricing of Initial Public Offering
posted by admin in Latest News

Read More
2019
18APR
Arrakis Therapeutics Announces $75 Million Series B Financing To Advance a New Class of Small-Molecule Medicines Targeting RNA
posted by admin in Latest News

Read More
2019
17APR
Turning Point Therapeutics prices IPO at $18, the high end of the range
posted by admin in Latest News

Read More
2019
27MAR
Precision BioSciences Announces Pricing of Initial Public Offering
posted by admin in Latest News

Read More
2019
12FEB
Harmony Biosciences Announces File Acceptance Of Its New Drug Application For Pitolisant
posted by admin in Latest News

Read More
2018
12DEC
Akero Therapeutics Announces $70 Million in New Financing
posted by admin in Latest News

Read More
2018
06DEC
Impel NeuroPharma Closes $67.5 Million Series D Financing
posted by admin in Latest News

Read More
2018
27NOV
Precision BioSciences Receives FDA Authorization to Initiate Clinical Study of Gene Edited Cancer Immunotherapy
posted by admin in Latest News

Read More
2018
07NOV
ALX Oncology Presents Updated Data from ALX148 Clinical Trial Combination Cohorts for the Treatment of Patients with Advanced Solid Tumors
posted by admin in Latest News

Read More
2018
19OCT
TP Therapeutics Completes $80 Million Mezzanine Financing Co-Led by Foresite Capital and venBio Partners
posted by admin in Latest News

Read More
2018
25JUN
Akero Therapeutics Closes $65 Million Series A Financing to Advance New Treatments for Serious Metabolic Diseases
posted by admin in Latest News

Read More
2018
17APR
TLR9 Agonist CMP-001-Pembrolizumab Combination Shows Early Efficacy in Patients With Metastatic Melanoma Resistant to Anti-PD-1
posted by admin in Latest News

Read More
2018
24JAN
Menlo Therapeutics Inc. Announces Pricing of Initial Public Offering of Common Stock
posted by admin in Latest News

Read More
2018
04JAN
Neurogastrx, Inc. Raises $45M Series A To Bring Lead GI Candidate Through Proof Of Concept
posted by admin in Latest News

Read More
2017
08NOV
Apellis Pharmaceuticals Announces Pricing of Initial Public Offering
posted by admin in Latest News

Read More
2017
05OCT
Harmony Biosciences Acquires US Rights To Pitolisant From Bioprojet; Raises $270 Million In Equity Financing
posted by admin in Latest News

Read More
2017
18JUL
venBio leads Series C Financing of oral once-daily Anti-Pruritus Therapy in development for Pruritus of Atopic Dermatitis, Psoriasis and Prurigo Nodularis, and for Refractory Chronic Cough
posted by admin in Latest News

Read More
2017
15JUNE
Checkmate Pharmaceuticals Secures $27 Million Series B Preferred Financing and Appoints Karen Brennan as Chief Operating Officer
posted by admin in Latest News

Read More
2017
10APR
Alexo Therapeutics Announces Initiation of Phase 1 Clinical Trial of ALX148 for the Treatment of Advanced Solid Tumors and Lymphoma
posted by admin in Latest News

Read More
2016
02DEC
Impel NeuroPharma Announces $36M Funding to Advance Novel Drug Delivery Platform for Central Nervous System Disorders
posted by admin in Latest News

Read More
2016
29NOV
Nabriva Announces Terms of Rights Offering
posted by admin in Latest News

Read More
2016
06MAY
venBio Closes $315 Million Life Sciences Venture Capital Fund
posted by admin in Latest News

Read More
2016
27MAR
Baxalta and Precision BioSciences form Global Genome Editing Collaboration in Immuno-Oncology
posted by admin in Latest News

Read More
2016
12FEB
Apellis Completes $47 Million Series D Financing
posted by admin in Latest News

Read More
2015
12AUG
Checkmate Pharmaceuticals Debuts with $20 Million Series A Investment For Development of Novel Immuno-Oncology Product Platform
posted by admin in Latest News

Read More
2015
05AUG
Metacrine Raises $36M in VC Funding, Focuses on Metabolic Diseases
posted by admin in Latest News

Read More
2015
11MAY
Precision BioSciences Lands $26M for Gene-Editing Technology
posted by admin in Latest News

Read More
2014
02JUL
VenBio Scores Again as Genentech Pays $1.7B+ for Seragon Pharma
posted by admin in Latest News

Read More
2014
01JUL
Genentech Announces Definitive Agreement to Acquire Seragon Pharmaceuticals
posted by admin in Latest News

Read More
2014
10JUN
As Its Investors Reap Returns, venBio Aims for a Bigger Second Fund
posted by admin in Latest News

Read More